Literature DB >> 2040803

A comparative study of the immunogenicity of pneumococcal type 4 polysaccharide and oligosaccharide tetanus toxoid conjugates in adult mice.

C C Peeters1, A M Tenbergen-Meekes, D E Evenberg, J T Poolman, B J Zegers, G T Rijkers.   

Abstract

A number of pneumococcal type 4 poly- and oligosaccharide tetanus toxoid conjugates were prepared using identical conjugation methods. Purified conjugates with similar m.w. were injected in mice; polysaccharide conjugates (PS4TT) were more immunogenic than oligosaccharide conjugates (OS4TT). Polysaccharide conjugates with a PS4:TT ratio less than 1 (w/w) appeared to be the most immunogenic conjugates. This was observed in both NIH (outbred) and BALB/c (inbred) strains of mice. Oligosaccharide tetanus toxoid conjugates required w/w ratios of greater than 1 to acquire optimal immunogenicity. Oligosaccharides (12 repeating units) of pneumococcal type 4, obtained by periodate cleavage, appeared to retain full antigenicity as measured by competition ELISA. Both PS4TT and OS4TT conjugates induced an antibody response with the characteristics of a T cell-dependent type of immune response. An anti-PS4 IgG and IgM booster effect could be demonstrated for all conjugates. The IgG subclass response induced by PS4TT and OS4TT conjugates is primarily IgG1 but IgG3 is also detectable. However, the amounts of anti-PS4 IgG3 differed for the various conjugates. We conclude that the immune response induced by pneumococcal type 4 saccharide tetanus toxoid conjugates can be manipulated by variation of the saccharide:protein ratio and the saccharide chain length, whereas keeping the m.w. of such conjugates at constant values.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2040803

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls.

Authors:  E Konadu; J Shiloach; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Induction of anti-pneumococcal cell wall polysaccharide antibodies by type 4 pneumococcal polysaccharide-protein conjugates.

Authors:  C Peeters; A M Tenbergen-Meekes; J Poolmann; B Zegers; G Rijkers
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

3.  Streptococcus pneumoniae type 14 polysaccharide-conjugate vaccines: length stabilization of opsonophagocytic conformational polysaccharide epitopes.

Authors:  C A Laferriere; R K Sood; J M de Muys; F Michon; H J Jennings
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

4.  Characterization of a recombinant pneumolysin and its use as a protein carrier for pneumococcal type 18C conjugate vaccines.

Authors:  J Kuo; M Douglas; H K Ree; A A Lindberg
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

5.  Outer membrane proteins as a carrier for detoxified lipooligosaccharide conjugate vaccines for nontypeable Haemophilus influenzae.

Authors:  T H Wu; X X Gu
Journal:  Infect Immun       Date:  1999-10       Impact factor: 3.441

6.  Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.

Authors:  R K Gupta; W Egan; D A Bryla; J B Robbins; S C Szu
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

7.  Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.

Authors:  Zhigang Jin; Chiayung Chu; John B Robbins; Rachel Schneerson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

8.  Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG.

Authors:  E Alonso de Velasco; A F Verheul; A M van Steijn; H A Dekker; R G Feldman; I M Fernández; J P Kamerling; J F Vliegenthart; J Verhoef; H Snippe
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

Review 9.  Pneumococcal polysaccharide vaccines: indications, efficacy and recommendations.

Authors:  G A Bruyn; R van Furth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-11       Impact factor: 3.267

10.  Immunogenicity of polysaccharides conjugated to peptides containing T- and B-cell epitopes.

Authors:  E Lett; S Gangloff; M Zimmermann; D Wachsmann; J P Klein
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.